Replies to post #141163 on Biotech Values

[genisi]

I can think of a couple but I imagine Protalix thinks that since the claims covering Enbel’s composition in patent #8,063,182 are specific to production of the protein in CHO cells (see for example claim #8), they might work around the AMGN patent by producing it in plant cell.